|
1
|
Morita H, Saito H, Matsumoto K and Nakae
S: Regulatory roles of mast cells in immune responses. Semin
Immunopathol. 38:623–629. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Huang H, Li Y and Liu B: Transcriptional
regulation of mast cell and basophil lineage commitment. Semin
Immunopathol. 38:539–548. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Boeckxstaens G: Mast cells and
inflammatory bowel disease. Curr Opin Pharmacol. 25:45–49. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Galli SJ, Nakae S and Tsai M: Mast cells
in the development of adaptive immune responses. Nat Immunol.
6:135–142. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gilfillan AM and Tkaczyk C: Integrated
signalling pathways for mast-cell activation. Nat Rev Immunol.
6:218–230. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Arthur G and Bradding P: New developments
in mast cell biology: Clinical implications. Chest. 150:680–693.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cardamone C, Parente R, Feo GD and
Triggiani M: Mast cells as effector cells of innate immunity and
regulators of adaptive immunity. Immunol Lett. 178:10–14. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Savage JH, Courneya JP, Sterba PM,
Macglashan DW, Saini SS and Wood RA: Kinetics of mast cell,
basophil and oral food challenge responses in omalizumab-treated
adults with peanut allergy. J Allergy Clin Immunol.
130:1123–1129.e2. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Andersson C, Tufvesson E, Diamant Z and
Bjermer L: Revisiting the role of the mast cell in asthma. Curr
Opin Pulm Med. 22:10–17. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Reber L, Da Silva CA and Frossard N: Stem
cell factor and its receptor c-Kit as targets for inflammatory
diseases. Eur J Pharmacol. 533:327–340. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lennartsson J and Rönnstrand L: Stem cell
factor receptor/c-Kit: From basic science to clinical implications.
Physiol Rev. 92:1619–1649. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lorentz A and Bischoff SC: Regulation of
human intestinal mast cells by stem cell factor and IL-4. Immunol
Rev. 179:57–60. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Al-Azzam N, Kondeti V, Duah E, Gombedza F,
Thodeti CK and Paruchuri S: Modulation of mast cell proliferative
and inflammatory responses by leukotriene d4 and stem cell factor
signaling interactions. J Cell Physiol. 230:595–602. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Faber TW, Pullen NA, Fernando JF, Kolawole
EM, McLeod JJ, Taruselli M, Williams KL, Rivera KO, Barnstein BO,
Conrad DH and Ryan JJ: ADAM10 is required for SCF-induced mast cell
migration. Cell Immunol. 290:80–88. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Smrž D, Bandara G, Beaven MA, Metcalfe DD
and Gilfillan AM: Prevention of F-actin assembly switches the
response to SCF from chemotaxis to degranulation in human mast
cells. Eur J Immunol. 43:1873–1882. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Stankov K, Popovic S and Mikov M: C-KIT
signaling in cancer treatment. Curr Pharm Des. 20:2849–2880. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
O'Laughlin-Bunner B, Radosevic N, Taylor
ML, Shivakrupa, DeBerry C, Metcalfe DD, Zhou M, Lowell C and
Linnekin D: Lyn is required for normal stem cell factor-induced
proliferation and chemotaxis of primary hematopoietic cells. Blood.
98:343–350. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fukao T, Yamada T, Tanabe M, Terauchi Y,
Ota T, Takayama T, Asano T, Takeuchi T, Kadowaki T, Hata Ji J and
Koyasu S: Selective loss of gastrointestinal mast cells and
impaired immunity in PI3K-deficient mice. Nat Immunol. 3:295–304.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
MacNeil AJ, Junkins RD, Wu Z and Lin TJ:
Stem cell factor induces AP-1-dependent mast cell IL-6 production
via MAPK kinase 3 activity. J Leukoc Biol. 95:903–915. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Moaaz M, Abo El-Nazar S, Abd El-Rahman M
and Soliman E: Stem cell factor and interleukin-31 expression:
Association with IgE among Egyptian patients with atopic and
Nonatopic bronchial asthma. Immunol Invest. 45:87–106. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lei Z, Liu G, Huang Q, Lv M, Zu R, Zhang
GM, Feng ZH and Huang B: SCF and IL-31 rather than IL-17 and BAFF
are potential indicators in patients with allergic asthma. Allergy.
63:327–332. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Samitas K, Delimpoura V, Zervas E and Gaga
M: Anti-IgE treatment, airway inflammation and remodelling in
severe allergic asthma: Current knowledge andfuture perspectives.
Eur Respir Rev. 24:594–601. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Anandan C, Nurmatov U, van Schayck OC and
Sheikh A: Is the prevalence of asthma declining? Systematic review
of epidemiological studies. Allergy. 65:152–167. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bulfone-Paus S and Bahri R: Mast cells as
regulators of T cell responses. Front Immunol. 6:3942015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li B, Berman J, Tang JT and Lin TJ: The
early growth response factor-1 is involved in stem cell factor
(SCF)-induced interleukin 13 production by mast cells, but is
dispensable for SCF-dependent mast cell growth. J Biol Chem.
282:22573–22581. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mitchell J, Dimov V and Townley RG: IL-13
and the IL-13 receptor as therapeutic targets for asthma and
allergic disease. Curr Opin Investig Drugs. 11:527–534.
2010.PubMed/NCBI
|
|
28
|
Corren J: Role of interleukin-13 in
asthma. Curr Allergy Asthma Rep. 13:415–420. 2013. View Article : Google Scholar : PubMed/NCBI
|
